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Leukotriene B4 mediates a variety of 
inflammatory diseases such as asthma, 
arthritis, atherosclerosis and cancer 
through activation of the G-protein coupled 
receptor, BLT1. Using in silico molecular 
dynamics simulations combined with site 
directed mutagenesis we characterized the 
ligand binding site and activation 
mechanism for BLT1.  Mutation of residues 
predicted as potential ligand contact points 
in transmembrane domains (TMs) III (H94, 
Y102A), V (E185A) and VI (N241A) 
resulted in reduced binding affinity. 
Analysis of arginines in extracellular loop 2 
(ECL2) revealed that mutating arginine 156 
but not arginine 171 or 178 to alanine 
resulted in complete loss of LTB4 binding to 
BLT1. Structural models for the ligand-free 
and ligand-bound states of BLT1 revealed 
an activation core formed around D64, 
displaying multiple dynamic interactions 
with N36, S100, N281 and a triad of serines, 
S276, S277 and S278.  Mutagenesis of many 
of these residues in BLT1 resulted in loss of 
signaling capacity while retaining normal 
LTB4 binding function. Thus, polar 
residues within TMs III, V and VI and 
ECL2 are critical for ligand-binding while 
polar residues in TMs II, III and VII play a 
central role in transducing the ligand-
induced conformational change to 
activation. The delineation of a validated 
binding site and activation mechanism 
should facilitate structure-based design of 
inhibitors targeting BLT1.  
 Seven transmembrane receptors 
widely known as G-protein coupled receptors 
(GPCRs) (1,2) mediate an array of 
physiological processes in response to such 
diverse agonists as peptides, amino acid 
derivatives and lipids. Despite the great 
diversity in their ligands, the conserved motifs 
found across this super family and the limited 
interacting partners such as G-proteins (3) and 
β-arrestins (4) at the cytoplasmic interface 
point towards a common activation 
mechanism for GPCRs. GPCRs constitute the 
single largest group of molecules for drug 
targets due to their critical importance in 
mediating biological responses as well as their 
easy accessibility on the cell surface. 
However, very little structural information is 
available for GPCRs due to difficulties in 
purifying and obtaining crystal structures for 
this class of receptors.  
 
 The availability of the rhodopsin 
crystal structure (5) combined with the 
approach of computational modeling and 
validation by site-directed mutagenesis has led 
to delineation of ligand-receptor interactions 
in a few GPCRs (6-9).  Some elements of the 
activation mechanism have been identified for 
individual GPCRs (1,6,8,10-12). Several 
studies employing site directed mutagenesis 
have helped uncover critical interactions 
between residues in transmembrane domains 
of the GPCRs (reviewed in (1)). The approach 
of computational modeling with validation by 
site-directed mutagenesis has led to significant 
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increases in the understanding of the processes 
involved in GPCR activation (6-9).  
   
Leukotriene B4 (LTB4) is a potent leukocyte 
chemoattractant and mediates its biological 
effects through two distinct G-protein coupled 
receptors, the high affinity receptor BLT1 and 
the low affinity receptor BLT2 (13,14). 
Several recent studies suggested a direct and 
critical role for BLT1 in diverse inflammatory 
diseases such as arthritis (15,16), 
atherosclerosis (17,18) and asthma (19). 
Recently, the high affinity LTB4 receptor, 
BLT1 was expressed in E.coli and shown to 
form a functional pentameric complex with 
hetero-trimeric G-proteins (20). 
Computational modeling has been used to 
investigate the potential role of the eighth 
helix in signaling of BLT1 (21,22). In 
addition, a recent study reported an LTB4 
binding site in BLT1 deduced from 
computational models (23). However, the 
exact nature of the LTB4 binding site and the 
potential changes in receptor conformation 
following LTB4 binding remain unknown.  
  
 In this study, computational modeling 
together with site-directed mutagenesis led to 
precise mapping and validation of the LTB4-
binding site in BLT1. Mutation of each of the 
residues predicted to be in the putative binding 
site resulted in reduced binding affinity. 
Furthermore, analysis of dynamic structures of 
the ligand-free and ligand-bound BLT1 
allowed prediction of critical movements of 
transmembrane helices and essential inter-
helical interactions stabilizing both the active 
and inactive states of the receptor. This 
analysis uncovered an activation core centered 
around D64 (D2.50-Ballesteros-Weinstein 
numbering system) (11) and comprised of 
polar amino acids N36 (N1.50), S100 (S3.35), 
S277 (S7.45), S278 (S7.46), S279 (S7.47) and 
N281 (N7.49) and led to the formulation of an 
activation mechanism. The deduced 
mechanism of BLT1 activation was consistent 
with the experimental observations made with 




Homology modeling and identification of 
LTB4 binding site in BLT1: The multiple 
alignment of the human LTB4 receptors, 
BLT1 and BLT2, with bovine rhodopsin was 
generated using CLUSTALW (24). The 
alignment was in agreement with known 
literature on helix stabilization motifs, 
disulphide linkage conservation and core 
forming residue conservation in GPCRs (25) 
and was used to generate homology models 
based on the crystal structure of Bovine 
Rhodopsin (5) (PDB id; 1F88.ent) as a 
template in Modeler (26). The homology 
model of BLT1 was energy minimized 
(hydrogen atom addition by xleap and 
minimized using 5000 steps of steepest 
descent followed by 20,000 steps of conjugate 
gradient using AMBER8 (27) sander with 
ff99) and then used for docking with LTB4. A 
structure for LTB4 was generated in 
SYBYL7.0 (SYBYL 7.0, Tripos Inc., 1699 
South Hanley Rd., St. Louis, Missouri, 63144, 
USA) and charges and potentials were 
assigned to the receptor (Kollman All) and 
ligand (gasteiger). A consensus docking 
approach was used wherein multiple docking 
algorithms were employed to improve the 
scoring process. LTB4 was docked into BLT1 
using, DOCK (28), SURFLEX (29) and 
AUTODOCK (30). The consensus structure 
for ligand docked BLT1 was refined using 
restricted molecular dynamics using the 
SYBYL7.0 dynamics module, employing the 
AMBER 7 FF99 for 500ps with a 1fs time 
step. The “aggregates” option was employed 
to keep frozen (fixed) all the parts of the 
receptor except the ligand and the ligand 
binding pocket as defined by a radius of 8Å 
with the ligand as center. The resulting 
structure was then energy minimized (5000 
steps of steepest descent followed by 20,000 
steps of conjugate gradient) and molecular 
dynamics simulations in vacuo, were carried 
out (100K, 25ps followed by 300 K for 125 ps 
with positional restraints of 1000 kcal (mol 
Å)-1) using AMBER8 (27) (sander ff99) on the 
entire receptor excluding the above defined 
binding pocket residues and the ligand, which 
were left unrestrained to further optimize 
contacts and relax the pocket. The binding 
mode was visualized using Insight II 
(Accelrys Inc) and SYBYL7.0. Figures were 
generated with Insight II, Molscript (31) and 
Raster3D (31). 
  










  Molecular Dynamics Simulations: 
Molecular dynamics simulations of the ligand-
bound and ligand-free forms of the receptor 
were carried out in a lipid bilayer solvated 
system consisting of lipid, water and ions 
using previously reported protocols (32). 
Specifically, xleap was used to generate the 
solvated lipid bilayer system, comprised of the 
homology model of BLT1, 375 pre-
equilibrated dodecyl maltoside lipid 
molecules, 10111 TIP3P solvent molecules 
and Cl- ions added for neutrality. Our standard 
equilibrium and production run protocols were 
used (32).  Molecular dynamics simulations 
were performed using the AMBER-99 force 
field using AMBER 8.0. and the mpi Sander 
module in the isothermal isobaric ensemble 
(p=1 atmosphere) and anisotropic pressure 
scaling (ntp=2); periodic boundary conditions 
with PME; 1.5 fs time step; hydrogen atoms 
frozen using SHAKE. The ligand was 
parameterized with antechamber program (33) 
using the GAFF (general amber force field) 
and HF/6-31G* derived RESP atomic charges 
from GAMESS. The production runs were 
unrestrained and run for 5 ns using 32 Opteron 
processors. The same protocol was followed 
for both BLT1 with and without the bound 
natural agonist, LTB4.  
 
 Molecular dynamics trajectories were 
analyzed via Energy versus Time and Root 
Mean Square Deviation (RMSD of backbone 
atoms) versus Time for the post equilibration 
production phase. The analysis established the 
energetic and structural stability of the system 
for both ligand-free and ligand-bound BLT1 
simulations.  
 
  Site directed mutagenesis: The construction 
of cDNA of hemagluttinin (HA) epitope 
tagged BLT1 was described previously (34). 
A Red Fluorescent Protein-Monomer (RFP-
Mono) was tagged at the C-terminus of BLT1 
by in frame cloning the entire coding region of 
the receptor without a stop codon ahead of the 
RFP-coding region in pDsRed-Monomer N1 
vector (BD biosciences # 632465). Site 
specific mutants of BLT1-RFP-Mono were 
generated using the PCR based sense-anti 
sense primer method (35) and all mutants 
were confirmed by DNA sequencing.  
 
 Expression of receptors and generation of 
clonal stable cell lines: Functional properties 
of the native and mutant receptors were 
examined in 300.19 cells. 300.19 is a murine 
pre-B cell line with no detectable endogenous 
expression of any LTB4 responsive receptors 
and was previously used to study the signal 
transduction pathways activated by leukocyte 
adhesion molecules (36) and chemokine 
receptors (37).  300.19 cells were maintained 
in RPMI supplemented with 10% FBS, 100 
U/ml penicillin, 100 µg/ml streptomycin and 
55 µM 2-mercaptoethanol and transfected by 
electroporation.   The stable single cell 
derived cell lines with BLT1 or its mutants 
were selected by FACS (Moflo) and 
maintained in the presence of 1 mg/ml of 
G418.  The cell surface expression was 
determined by incubating parental cells or 
cells expressing different receptor variants 
with 12CA5 antibody followed by FITC-
labeled goat anti-mouse IgG and analyzed 
using BD FACScalibur. 
 
  Ligand binding: Whole cell competition 
ligand binding (34) or saturation binding (13) 
assays were performed with 300.19 cells 
expressing BLT1 or its mutants. For 
competition binding assay, the cells (0.5 X 106 
per assay) were incubated with 2.5 nM 3[H] 
LTB4 (0.25 nM for BLT1) (163 Ci/mmol; 
Perkin Elmer, Boston, MA) along with 
increasing concentrations of cold ligand 
(Cayman chemicals, Detroit, MI) in binding 
buffer (50 mM Tris-HCl pH 7.4, 10 mM 
MgCl2, 10 mM NaCl, 0.05% BSA (Fatty acid 
free Fraction V, Sigma # A8806)). These 
mixtures were incubated on ice with gentle 
agitation for 2 h followed by rapid filtration 
through GF/C filters (Whatman #1822-025) 
using Manifold-Vacuum setup and washed 
with 3 ml of ice cold binding buffer. The 
radioactivity of the filters was determined 
with Beckman Coulter LS6500 Multi Purpose 
Scintillation Counter. Nonspecific binding 
was determined by inclusion of 2 µM 
unlabeled LTB4 to the cells suspended in 2.5 
nM 3[H] LTB4.  The competition curves were 
generated using Non-linear regression fit on 
Graphpad PRISM software and the EC50 
determined. 
 










  Saturation binding was also 
performed using whole cells. The binding 
mixture contained whole cells and 3H–LTB4 at 
various concentrations with or without 
unlabeled LTB4 in 1,000 fold excess. The 100 
µL binding reactions were incubated at 4 °C 
for two hours followed by rapid filtration 
through GF/C filters and radioactivity was 
measured as described above.  The saturation 
binding curves were generated using one site 
binding (hyperbola) non-linear regression 
curve fitting (Graphpad PRISM 4.0). Kd and 
Bmax were determined from these curves and 
expressed as nM and binding sites/cell, 
respectively.  Similar values were obtained 
from Scatchard analysis of the data.  
  
  Chemotaxis and calcium measurements: 
Migration of 300.19 cells was evaluated using 
5-µm pore size Transwell filters (Corning 
Costar, Cambridge, MA). Cells (1x 107) were 
resuspended in 1 ml of chemotaxis buffer 
(RPMI-1640, 1% FBS). The lower chamber 
was loaded with various concentrations of 
LTB4 in a volume of 600 µL and 100 µL 
(1x106 cells) of cells from above cell 
suspension was placed onto the upper 
chamber. After 3 h of incubation at 37 °C in 
5% CO2, the upper chamber was removed and 
cells in the lower chamber were counted in a 
Bürker chamber. Calcium mobilization was 
monitored in INDO-I loaded cells (300.19 
cells expressing BLT1-WT or its mutants) 
stimulated with various concentrations of 
LTB4 as previously described (34).   
 
  Receptor phosphorylation: 300.19 cells (5 
million cells per sample) expressing BLT1-
RFP or its mutants were serum-starved for 2 h 
in 5 ml phosphate-free DMEM medium with 
20 mM HEPES, pH 7.0. Cells were washed 
with the same buffer and labeled with 32P-
orthophosphate (150 µCi per sample; 8500-
9120 Ci/mmol, Perkin Elmer, Boston, MA) in 
above buffer in the total volume of 1.5 ml for 
1.5 hrs and cells were stimulated for 5 min at 
37 °C with LTB4 at indicated concentrations. 
Cells were washed twice with ice cold 1X 
PBS (w/o Ca2+ and Mg2+) containing 0.1% 
BSA. The harvested cells were lysed with 1 
ml of RIPA Buffer (50 mM Tris-Cl (pH 8), 
150 mM NaCl, 1%  NP-40, 0.5% 
deoxycholate,  0.1% SDS, 1 mM EDTA, 1 
mM NaF, 1 mM Sodium pyrophosphate and 
protease cocktail inhibitor tablet from Roche). 
HA-tagged receptors were immuno-
precipitated with high affinity anti-HA 
antibody (clone 3F10 from Roche). 
Immunoprecipitates were resolved by 10% 
SDS-PAGE and dried gels were exposed to 
phosphor imager screens and analyzed on 
Typhoon 9400 (Amersham BioSciences). 
Integrated counts were evaluated using 
ImageQuant software (Amersham 
Biosciences).  
  
  Real-time Fluorescence Microscopy: RBL-
2H3 cells were co-transfected with β-arrestin-
GFP and either with wild type or mutant 
receptor tagged with RFP (Mono) and images 




  Identification of LTB4 binding site in 
BLT1: Bovine rhodopsin had been the only 
available crystal structure (5) for a GPCR and 
hence heavily relied upon for homology 
modeling based approaches for structural 
studies of GPCRs. The rhodopsin ligand (11-
cis retinal) is covalently linked to the receptor 
whereas LTB4 is a mostly hydrophobic lipid 
with three nodes of polarity. The polar head 
group is a carboxylate which can form 
hydrogen bonding or strong ionic interactions, 
and the hydroxyl groups at the 5th and 12th 
carbon positions are also capable of forming 
hydrogen bonding interactions. 
 
  To obtain a starting structure for 
BLT1, a sequence alignment of human BLT1 
with bovine rhodopsin (1F88) was generated. 
This alignment was then manually modified to 
precisely match the known motifs in the 
transmembrane (TM) regions for rhodopsin 
with those of BLT1. A homology-based 3-
dimensional structural model for the human 
BLT1 that included a conserved disulphide 
linkage between Cys90-Cys168 (25,38) was 
generated and energy minimized. 
   
 A “consensus docking protocol” that 
used three independent docking algorithms: 
AUTODOCK (30), SURFLEX (29) and 
DOCK (28), was employed to obtain a ligand-
docked structure for BLT1. The top three 










ranked results from each of the docking runs 
were analyzed, and the highest common factor 
or the most common binding mode was 
selected as a starting binding mode for LTB4 
in BLT1. This structure of LTB4 docked into 
BLT1 was subjected to minimization and in 
vacuo molecular dynamics allowing both the 
receptor binding pocket and the ligand to relax 
and attain stable conformations of lowest 
energies. A snake diagram depicting the 
primary sequence of BLT1 is shown in Fig 
1A.  The residues identified as ligand contact 
points are marked in green. The structure of 
LTB4 bound to BLT1 is shown in (Fig. 1B). 
The ligand-binding site of BLT1 is composed 
of ECL2, TMs III, V and VI and the 
hydrophobic ligand penetrates deep into the 
transmembrane domains.  The three nodes of 
polar-regions in the ligand are countered by 
corresponding polar residues in the receptor. 
A clear ligand-binding pocket is visible in the 
surface rendering of the LTB4 binding site of 
BLT1 (Fig. 1C).  
 
  LTB4 interaction with residues in 
transmembrane domains: The hydrophobic 
nature of the ligand suggested a deep seated 
pocket within BLT1. Analysis of the ligand 
bound structure identified several potential 
contact points in the TMs: H94 and Y102 (TM 
III), E185 (TM V) and N241 (TM VI) while 
the polar head group was oriented towards 
ECL2 (Fig. 2A).  Both E185 (TM V) and 
Y102 (TM III) stabilize LTB4 binding by 
direct hydrogen bonding with the C5’ 
hydroxyl group as well as with each other 
whereas N241 (TM VI) hydrogen bonds to the 
hydroxyl group on C12’ of LTB4 at the base 
of the binding pocket. H94 likely interacts 
with the C5’-hydroxyl of LTB4 via hydrogen 
bonding. 
  
 To validate these interactions, 
receptor variants were generated by 
mutagenesis. Amino acid residues H94, Y102, 
N241 and E185 were mutated to alanine in a 
combination of single and double mutants. All 
these receptor variants were stably expressed 
to similar levels as single cell derived lines on 
the surface of 300.19 cells (Fig. 2B). All the 
mutants displayed reduced levels of binding as 
determined by both competition and saturation 
binding assays (Fig. 2C, D, E and Table 1). 
The four single mutants H94A, Y102A, 
N241A, and E185A displayed reduced 
binding affinity of 4 to 9 fold in competition 
binding and 6 to 15 fold in saturation binding 
assays (Table 1). Surface expression as 
measured by flow cytometry or as Bmax in 
saturation binding assays also showed that all 
mutants are expressed at comparable or higher 
levels relative to BLT1 (Table 1). The 
Y102A/N241A double mutant showed a 
synergistic reduction in binding affinity in 3H-
LTB4 binding assays (Fig. 2E and Table 1). 
LTB4 activates a variety of cellular responses 
including chemotaxis (14), calcium 
mobilization, ligand-induced phosphorylation 
and desensitization (39). Consistent with the 
reduction in binding, all the mutants showed a 
shift in dose response of chemotaxis (Fig. 2F) 
while retaining the bell-shaped nature of the 
response. The Y102A/N241A double mutant 
required 100 times more LTB4 for reaching 
the maximum response. Analysis of ligand-
induced calcium mobilization also showed a 
clear shift in dose response with each of these 
mutants (Fig. 3).  The Y102A, H94A, N241A 
and the Y102A/N241A double mutants 
reached similar levels of maximum activity 
but at much higher concentrations than the 
wild type receptor (Fig. 3). A summary of the 
functional properties of all the mutants is 
shown in (Table 1). 
 
  A Critical role for ECL2 in LTB4 binding: 
The ligand-docked structural model showed 
R156 and T157 being located on ECL2 which 
caps the binding site on top of the TM helix 
bundle. A charge interaction between R156 
and the carboxylate group of LTB4 was 
predicted to stabilize LTB4 in the binding 
pocket. The model also predicted T157 as 
being within hydrogen bonding distance of the 
carboxylate head group of LTB4. The other 
possible charge interactions on ECL2 were 
with R171 and R178.  
   
 In order to delineate the relative 
contribution of these residues to ligand 
binding, the R156A/T157A (RT/AA), 
R171A/R178A (RR/AA), R156A and T157A 
mutants were stably expressed to similar 
levels in 300.19 cells (Table 1). The 
R156A/T157A and the R156A mutants failed 
to show any [3H]-LTB4 binding, whereas the 










T157A and R171A/R178A mutants displayed 
similar ligand binding affinity as BLT1 (Table 
1). Consistent with the complete lack of LTB4 
binding the R156A/T157A and R156A 
mutants did not show a detectable chemotactic 
response (Fig 4A). In contrast, both the 
T157A and R171A/R178A mutants showed a 
similar bell shaped chemotaxis response as 
BLT1 (Fig 4A).  Likewise, ligand-induced 
calcium mobilization by all these mutants 
followed a similar profile with R156A/T157A 
and the R156A mutants showing a minimal 
response and T157A and R171A/R178A 
showing a similar response as BLT1. Thus, 
R156 is a critical residue for LTB4 binding, 
and as a consequence, for signaling in BLT1.  
 
  Ligand-Induced phosphorylation of BLT1 
mutants: Concomitant with activation, ligand 
binding induces a dose-dependent 
phosphorylation of the GPCRs by G-protein 
coupled receptor kinases (GRKs) (40) leading 
to desensitization of signaling. Previous 
studies have shown that BLT1 displays a basal 
level of phosphorylation that is enhanced by 
treatment with LTB4 (34).  (Fig. 5) shows that 
BLT1 undergoes rapid LTB4 dose-dependent 
phosphorylation and all the binding site 
mutants also displayed ligand-induced 
phosphorylation but required higher LTB4 
concentrations to be fully phosphorylated. The 
RT mutant while displaying basal 
phosphorylation did not show any further 
increase in receptor phosphorylation at any 
concentration of LTB4. 
 
Inactive and Active States of BLT1: An 
experimentally validated ligand binding mode 
in BLT1 described above formed the basis to 
examine the ligand-induced conformational 
changes in BLT1. Lipid bilayer molecular 
dynamics simulations were run for the ligand-
free and ligand-docked homology modeled 
structures of BLT1 to generate optimized 
inactive and active state models. A comparison 
of the models of the ligand-free and ligand-
bound states of BLT1 by superimposition 
revealed movement of transmembrane helices 
(Fig. 6A and 6B) as well as conformational 
changes at the amino acid level (see 
below). TMs I, II and IV show minimal 
movement, TMs III and V show moderate 
movement, and TMs VI and VII show the 
largest transmembrane helical movement (Fig 
6A and 6B). The large conformational changes 
observed in TMs VI and VII of BLT1 are 
consistent with similar changes associated 
with the activation of rhodopsin (41-43). 
  
 Identification of an Activation Core in 
BLT1: Hydrogen bonding, Van der Waals and 
electrostatic interactions were analyzed for 
both the inactive and active states of BLT1. A 
cluster of polar residues comprised of N36, 
D64, S100, N281, S277, S278 and S279 were 
found to differentially stabilize the inactive 
and active states of BLT1 and form the 
activation core. (Fig. 7A & 7B) Both, in the 
inactive (Fig. 7A) and active states (Fig. 7B), 
D64 was the hub of the interactions. In the 
inactive state, D64 was hydrogen bound with 
S100 (d = 2.6Å) and S278 (d = 2.7Å). The 
S100-D64 and S278-D64 interactions were 
conserved in both the inactive and active 
states of BLT1 (Fig. 7A and 7B). During 
activation, N281 and N36 moved upwards by 
3.2Å and 7Å (Fig 7B) respectively to 
hydrogen bond with D64. These interactions 
are completely absent in the inactive state (Fig 
7A).  
 
To determine the validity of this 
activation mechanism each of these polar 
residues were mutated to alanine and the 
mutant receptors were stably expressed to 
similar levels in clonal lines of 300.19 cells 
(Fig. 7C and Table 2). All of these mutants 
displayed ligand-binding affinity similar to the 
wild type BLT1 both in competition and 
saturation binding assays (Table 2) with the 
exception of the S277-79A mutant that bound 
LTB4 with reduced affinity (Table 2). 
Saturation binding analysis also showed that 
each of the mutants is expressed at similar or 
higher levels relative to BLT1 (Table 2). 
 
Analysis of the activation core 
mutants for chemotaxis, calcium mobilization, 
ligand-induced phosphorylation, β-arrestin 
association and internalization revealed severe 
reduction in their activity relative to BLT1. 
First, all mutants displayed reduced 
chemotaxis with N281A showing a complete 
loss of response (Fig. 7D). D64A and S277-
79A showed a shift as well as a reduction in 
response. Despite the significant reduction in 










magnitude, all mutants showed a bell shaped 
chemotaxis curve indicating normal gradient 
sensing by these mutants. 
  
Dose dependent calcium mobilization 
also showed a severe reduction in response for 
many of these mutants (Fig 8A-D). While the 
maximum response reached for the D64A 
mutant was only ~25% that of the BLT1 
response, other mutants reached 60 to 100% 
response to that of native BLT1. However, 
much greater inhibition was seen at the EC90 
of the BLT1 response, where for most mutants 
the response ranged from 0 to 10%.  In 
particular, the D64A and N281A mutants 
showed very little response at 1.0 and 10 nM 
LTB4 (Fig. 8 B and C, Table 2). Thus, despite 
similar binding affinity for LTB4, these BLT1 
mutants fail to convert ligand binding into an 
effective cytoplasmic signal. Simultaneous 
with receptor activation, ligand binding affects 
a dose dependent phosphorylation of GPCRs 
by G protein coupled receptor kinases (GRKs) 
(40) leading to desensitization as well as 
association of the phosphorylated receptors 
with β-arrestin.  BLT1 and all the activation 
core mutants showed a basal level of receptor 
phosphorylation as well as a comparable 
increase in PMA-induced phosphorylation 
(44) (Fig. 8E and 8F). While BLT1 showed a 
robust increase in ligand-induced 
phosphorylation, most activation core mutants 
displayed relatively weak ligand-induced 
phosphorylation (Fig. 8E and 8F). Consistent 
with the complete loss of chemotaxis response 
and severe reduction in calcium mobilization, 
the N281A mutant showed no ligand-induced 
phosphorylation but was a substrate for PMA-
induced phosphorylation.  Translocation of 
cytoplasmic β-arrestin to the membrane is a 
ubiquitous phenomenon following GPCR 
activation (45). (Fig 8G) shows the typical 
rapid β-arrestin translocation following LTB4 
treatment of cells expressing BLT1-RFP and 
β-arrestin-GFP. In this assay N281A failed to 
interact with arrestin, whereas the other 
mutants displayed relatively weak or delayed 
association of β-arrestin with RFP-receptors 
(Fig. 8G). Thus, despite similar binding 
affinity for LTB4, these BLT1 mutants fail to 





 Computational models identified the 
potential contact points for LTB4 in BLT1 that 
were validated by mutational analysis. 
Molecular dynamics analysis of the ligand- 
free and ligand-bound structural models of 
BLT1 predicted essential residues involved in 
differentially stabilizing the inactive and active 
states of the receptor via critical polar 
interactions. Experimentally, these were 
proven to affect the signaling mechanism 
supporting a conceptual activation core in 
class A GPCRs. A high degree of conservation 
of the polar activation core residues across the 
class A GPCRs lends further support for the 
mechanism. 
 The use of multiple docking protocols 
and molecular dynamics of the binding pocket 
allowed the delineation of the LTB4 binding 
site in BLT1. Experimental results with 
mutants support the accuracy of the predicted 
binding mode, validating this approach. The 
hydrophobic nature of LTB4 dictates to a large 
extent it’s deep seated binding mode in the 
BLT1 pocket. The ligand is encompassed by 
transmembrane domains III, V and VI, while 
ECL2 forms a lid over the pocket. Each of the 
three TM’s contribute residues towards ligand 
binding (H94 and Y102 in TM-III, E185 in 
TM-V and N241 in TM-VI). The three nodes 
of polarity in LTB4 are being countered by 
four polar residues in the receptor and 
mutation of each had a measurable effect on 
binding affinity and signaling. The N241A, 
Y102A, E185A, H94A and the Y102A-
N241A double mutant, each attained the wild 
type maximum levels of signaling in 
functional assays including chemotaxis, 
calcium flux and receptor phosphorylation, 
albeit at a much higher concentration of LTB4 
as compared to BLT1. This suggests that 
while these residues located in TMs III, V and 
VI contribute to the binding affinity by 
countering the hydroxyl groups at 5th and 12th 
positions on LTB4, they are not absolutely 
critical for LTB4 binding or ligand–induced 
conformational changes associated with 
receptor activation. In contrast, interaction of 
the carboxylate head group with ECL2 is 
absolutely critical for binding. While both 
R156 and T157 were predicted to be involved 










in ligand binding, analysis of double and 
single mutants established the critical role of 
R156 in LTB4 binding.  Mutation of arginine 
156 to alanine resulted in minimal levels of 
signaling as expected from the complete loss 
of ligand binding. These findings suggest a 
more critical role for ECL2 residues in LTB4 
binding than that for the transmembrane 
domains. The negative charge of the 
carboxylate head group of LTB4 is effectively 
countered by the positively charged arginine 
residue (R156). The ECL2 may be involved in 
initial ligand entry as well as being critical for 
ligand stabilization via a hinged lid-like action 
closing and completing the binding pocket. An 
integral role for ECL2 in ligand binding has 
also been reported for other GPCRs (46,47). 
 A recent study reported a molecular 
modeling based binding pocket for LTB4 in 
BLT1 (23). The study concludes with the 
identification of Arg178 and Glu185 as 
residues involved in ligand receptor 
interactions and Val 105 and Ile 108 as lining 
the binding pocket. In general, the overall 
binding modes described here and in Sabirsh 
et al. (23) are similar in that the orientation of 
the ligand along the receptor axis, with the 
hydrophobic tail seated deep in the core and 
the polar head group pointing towards the 
extracellular surface. Secondly, the E185 was 
identified as a ligand binding residue by both 
models via interaction with the C5’hydroxyl 
group of LTB4.  
 
However, the binding mode proposed 
here differs from Sabirsh et al. with respect to 
identification of the residues involved in 
ligand stabilization, the magnitude of the 
effects of point mutations on ligand binding 
and the experimental and computational 
strategies employed to arrive at these 
conclusions. The studies here identify and 
validate H94, Y102, N241 and R156 as 
residues involved in LTB4 binding to BLT1 
while none of these residues were considered 
by Sabirsh et al. (23). In contrast, they have 
indicated R178 as a binding site residue based 
on the R178L mutation. The magnitude of the 
effect on ligand binding observed in Sabirsh et 
al. upon mutating Arg178 to Leu could 
possibly be a result of the energetic penalty 
arising out of replacing a polar residue by a 
highly hydrophobic residue. In our study, 
mutating R178 to alanine had no effect on 
ligand binding. In contrast, it is the R156 on 
ECL2 that is most critical for LTB4 binding as 
evidenced by complete loss of binding in the 
R156A mutant while being expressed 
normally on the cell surface. Alanine 
substitution was used as a mutagenesis 
strategy for all our analysis as this would 
minimize other indirect effects. 
 
 The differences in the structural 
models may be accounted for by the 
contrasting computational strategies 
employed. While Sabirsh et al. based their 
model of BLT1 on a theoretical active state 
model of rhodopsin; our models were based on 
the crystal structure of inactive state bovine 
rhodopsin (PDB id: 1F88.ent). In our studies, 
LTB4 was successfully docked into the 
inactive state of BLT1 in a minimum energy 
conformation following a consensus docking 
approach. It is important to note that docking 
LTB4 into a lipid bilayer simulated structure of 
BLT1 in it self was insufficient to accurately 
identify all the interactions.  Further, the use of 
fully solvated lipid bilayer molecular 
dynamics simulations might better 
approximate the receptor microenvironment as 
compared to energy minimized homology 
models developed by Sabirsh et al. (23).  
  
 A few of the residues identified in this 
study as being critical to LTB4 binding in 
BLT1 have been implicated in mediating 
ligand binding via congruent positions in other 
class A GPCRs. The E185 residue in BLT1 
finds a parallel in the E182 residue of the 
histamine binding site of the histamine H4 
receptor (48). Similarly, an equivalent of the 
H94 residue (TM III) has been shown to play a 
critical role in ligand recognition in the human 
A3 adenosine receptor as H95 (49). The fMLP 
binding site in its receptor was dissected using 
a chimeric approach and revealed the essential 
role of extracellular loops in ligand binding 
(50). An essential role for R156 (ECL2) in 
ligand binding in BLT1 was established in this 
study. Interestingly, arginines in ECL2 were 
shown to be important in ligand binding in 
several other chemoattractant receptors. In 
prostaglandin D2 receptor (CRTH2) R178A 
mutation in ECL2 resulted in a five fold 
decrease in the binding affinity (51). In CCR5, 










R168 in ECL2 is essential for binding MIP1 
alpha (52). Similarly, it has been shown in the 
C5a receptor that arginine 175 is an important 
counter-ion in binding C5a. In CXCR3, 
arginine 197 and arginine 212 in ECL2 are 
critical for ligand binding whereas arginine 
216 is critical for receptor activation but not 
for ligand binding or internalization (53). 
Given the chemical diversity of the GPCR 
ligands, these examples highlight the role of 
arginines in ECL2 in ligand binding in 
GPCRs.  
 
The residues Y102, R156, E185 and 
N241 are all conserved in the low affinity 
LTB4 receptor BLT2 but the H94 is replaced 
by Y in BLT2. Despite the limited homology 
between BLT1 and BLT2 (~45%), 
conservation of most of the binding site 
residues described here suggests a common 
binding mode for LTB4 in BLT1 and BLT2. 
The difference in the binding affinities 
between BLT1 and BLT2 for LTB4 may thus 
be related to the replacement of H94 with Y 
and other possible changes in helical 
orientation and/or interaction distances 
between the key binding residues in BLT2. 
Application of similar strategies described 
here should allow precise identification and 
rationalization of LTB4 binding site in BLT2. 
The elucidation of the LTB4 binding site 
renders BLT1 amenable to structure based 
drug design. 
 
The BLT1 structures with and without 
bound LTB4 allowed delineation of the ligand-
induced conformational changes leading to a 
preliminary activation mechanism. In the 
generalized toggle switch activation 
mechanism (54) of GPCRs, TM VI (55) and 
VII (42) are known to move outwards at the 
extracellular face of the receptor. Similar 
helical movements were observed for BLT1 
activation, and the final alignment of TM VI 
and VII were consistent to both in rhodopsin 
(12,41,55) and in the generalized toggle switch 
mechanism. Upward and downward 
movements of the helices resulted in an 
increased cytoplasmic penetration of ICL’s 2 
and 3 in the active state of the receptor. This, 
along with a more open arrangement of the 
TMs at the cytoplasmic face, is consistent with 
the need for increased surface area for 
interaction with signaling partners such as G-
proteins and β-arrestin. The model for BLT1 is 
also consistent with respect to only minimal 
changes being seen for TMs I through IV (54).  
  
A unique element of the current study 
is that molecular dynamic simulations were 
predictive and allowed rationalization of 
global changes in receptor conformation to 
altered interactions at the level of a few amino 
acid residues. These residues couple the 
ligand-binding domain to signaling via 
appropriate conformational changes. The 
receptor variants generated by site-directed 
mutagenesis of the activation core residues 
allowed uncoupling of ligand binding function 
from signaling function. Both D64A and 
N281A mutants bind LTB4 with the same 
affinity as BLT1 yet activate minimal 
signaling functions. Thus, reorientation of 
helix VII bringing the N281 in juxtaposition to 
D64 appears a critical event for stabilizing the 
active state of BLT1. The D64-N281 
interaction has been implicated as being 
critical in several other GPCRs.(1,6,8) An 
interesting difference in the GnRH (56) 
receptor is D64 and N281 are replaced by N87 
and D318. The residues when reversed at this 
position retained wild type receptor functions, 
whereas single mutants were defective in 
ligand binding. In the case of the serine triad 
S277-79 the interactions were more complex, 
as W234 stabilizes the inactive state via 
hydrogen bonds with S278 but switches to 
S277 in the active state.  In the serine triad 
mutant loss of stabilizing forces both in the 
active and inactive states of the receptor might 
have resulted in the observed phenotype of 
both reduced binding affinity as well as 
signaling capacity.  
 
The general applicability of the 
proposed BLT1 mechanism to other class A 
GPCRs was examined in 1636 sequences from 
the GPCR data base (www.gpcr.org). The 
activation core residues at positions N36, D64, 
S100, S277, S278, S279, and N281 occur at a 
frequency of N36 (100 %), D64 (91.25%), 
S100 (<1%), S277 (13.5%), S278 (29.9%), 
S279 (6.8%) and N281 (64%). At the “SSS” 
locus, depending on the receptor subclass there 
exist other common motifs for GPCRs such as 
HCC, NSC, NSS and other such combinations 










of polar residues. Of the 1636 GPCRs 
analyzed nearly 100% have conserved polar 
residues at positions equivalent to N36 and 
D64, while other positions also showed high 
levels of polar residue conservation across 
class A GPCRs (Table-3). Thus, at congruent 
positions to those identified in BLT1, 
conservation of polarity rather than exact 
identity of the residues might be critical for 
GPCR function (57,58). It is possible that each 
of these conserved positions in other GPCRs 
represent similar elements of the activation 
mechanism as seen for BLT1. 
 
The polar residues comprising the ligand 
binding site and activation core are critical in 
coupling LTB4 binding to signaling in BLT1. 
Further studies will establish the significance 
of hydrophobic residues in receptor function.   
 
Acknowledgements: This work was 
supported by the NIH grant AI52381 to BH 
and SB was supported by an American Heart 
Association Pre-doctoral award. 
 
Abbreviations: GPCR: G-Protein coupled 
receptors, ECL: Extracellular loop, ICL: 
intracellular loop, BLT1: Leukotriene B4 
Receptor-1, BLT2: Leukotriene B4 Receptor-2 
LTB4: Leukotriene B4, TM: Transmembrane, 
MD: Molecular dynamics, FF- Force field, 
PS: Pico seconds, NS: Nano seconds, RFP: 
Red fluorescence protein, GFP: Green 
fluorescence protein, FITC: Fluorescein 
Isothiocyanate, HA: Hemaggluttinin Antigen, 
FBS: Fetal bovine serum, EC50: Effective 
concentration 50, BSA: Bovine serum 
albumin, SDS-PAGE: Sodium Dodecyl 
Sulfate Polyacrylamide Gel Electrophoresis, 






1. Kristiansen, K. (2004) Pharmacol Ther 103, 21-80 
2. Gether, U. (2000) Endocr Rev 21, 90-113 
3. Cabrera-Vera, T. M., Vanhauwe, J., Thomas, T. O., Medkova, M., Preininger, A., Mazzoni, 
M. R., and Hamm, H. E. (2003) Endocr Rev 24, 765-781 
4. Lefkowitz, R. J., and Shenoy, S. K. (2005) Science 308, 512-517 
5. Palczewski, K., Kumasaka, T., Hori, T., Behnke, C. A., Motoshima, H., Fox, B. A., Le Trong, 
I., Teller, D. C., Okada, T., Stenkamp, R. E., Yamamoto, M., and Miyano, M. (2000) Science 
289, 739-745 
6. Urizar, E., Claeysen, S., Deupi, X., Govaerts, C., Costagliola, S., Vassart, G., and Pardo, L. 
(2005) J Biol Chem 280, 17135-17141 
7. Fanelli, F., and De Benedetti, P. G. (2005) Chem Rev 105, 3297-3351 
8. Jongejan, A., Bruysters, M., Ballesteros, J. A., Haaksma, E., Bakker, R. A., Pardo, L., and 
Leurs, R. (2005) Nat Chem Biol 1, 98-103 
9. Spijker, P., Vaidehi, N., Freddolino, P. L., Hilbers, P. A., and Goddard, W. A., 3rd. (2006) 
Proc Natl Acad Sci U S A 103, 4882-4887 
10. Decaillot, F. M., Befort, K., Filliol, D., Yue, S., Walker, P., and Kieffer, B. L. (2003) Nat 
Struct Biol 10, 629-636 
11. Sealfon, S. C., Chi, L., Ebersole, B. J., Rodic, V., Zhang, D., Ballesteros, J. A., and 
Weinstein, H. (1995) J Biol Chem 270, 16683-16688 
12. Sakmar, T. P., Menon, S. T., Marin, E. P., and Awad, E. S. (2002) Annu Rev Biophys Biomol 
Struct 31, 443-484 
13. Yokomizo, T., Kato, K., Terawaki, K., Izumi, T., and Shimizu, T. (2000) J Exp Med 192, 
421-432 
14. Yokomizo, T., Izumi, T., Chang, K., Takuwa, Y., and Shimizu, T. (1997) Nature 387, 620-
624 
15. Kim, N. D., Chou, R. C., Seung, E., Tager, A. M., and Luster, A. D. (2006) J Exp Med 203, 
829-835 










16. Shao, W. H., Del Prete, A., Bock, C. B., and Haribabu, B. (2006) J Immunol 176, 6254-6261 
17. Helgadottir, A., Manolescu, A., Helgason, A., Thorleifsson, G., Thorsteinsdottir, U., 
Gudbjartsson, D. F., Gretarsdottir, S., Magnusson, K. P., Gudmundsson, G., Hicks, A., 
Jonsson, T., Grant, S. F., Sainz, J., O'Brien, S. J., Sveinbjornsdottir, S., Valdimarsson, E. M., 
Matthiasson, S. E., Levey, A. I., Abramson, J. L., Reilly, M. P., Vaccarino, V., Wolfe, M. L., 
Gudnason, V., Quyyumi, A. A., Topol, E. J., Rader, D. J., Thorgeirsson, G., Gulcher, J. R., 
Hakonarson, H., Kong, A., and Stefansson, K. (2006) Nat Genet 38, 68-74 
18. Jala, V. R., and Haribabu, B. (2004) Trends in Immunology 25, 315-322 
19. Miyahara, N., Takeda, K., Miyahara, S., Matsubara, S., Koya, T., Joetham, A., Krishnan, E., 
Dakhama, A., Haribabu, B., and Gelfand, E. W. (2005) Am J Respir Crit Care Med 172, 161-
167 
20. Baneres, J. L., and Parello, J. (2003) J Mol Biol 329, 815-829 
21. Okuno, T., Ago, H., Terawaki, K., Miyano, M., Shimizu, T., and Yokomizo, T. (2003) J Biol 
Chem 278, 41500-41509 
22. Okuno, T., Yokomizo, T., Hori, T., Miyano, M., and Shimizu, T. (2005) J Biol Chem 280, 
32049-32052 
23. Sabirsh, A., Bywater, R. P., Bristulf, J., Owman, C., and Haeggstrom, J. Z. (2006) 
Biochemistry 45, 5733-5744 
24. Eddy, S. R. (1995) Proc Int Conf Intell Syst Mol Biol 3, 114-120 
25. Rader, A. J., Anderson, G., Isin, B., Khorana, H. G., Bahar, I., and Klein-Seetharaman, J. 
(2004) Proc Natl Acad Sci U S A 101, 7246-7251 
26. Sali, A., and Blundell, T. L. (1993) J Mol Biol 234, 779-815 
27. Case, D. A. e. a. (2004) University of California Sanfrancisco  
28. Ewing, T. J., Makino, S., Skillman, A. G., and Kuntz, I. D. (2001) J Comput Aided Mol Des 
15, 411-428 
29. Jain, A. N. (2003) J Med Chem 46, 499-511 
30. Morris GM, G. D., Halliday RS, Huey R, Hart WE, Belew RK, Olson AJ. (1998) J Comp 
Chem 19, 1639-1662 
31. Merritt, E. A., and Murphy, M. E. (1994) Acta Crystallogr D Biol Crystallogr 50, 869-873 
32. Trent, J. O., Wang, Z. X., Murray, J. L., Shao, W., Tamamura, H., Fujii, N., and Peiper, S. C. 
(2003) J Biol Chem 278, 47136-47144 
33. Wang, J., Wang, W., Kollman, P. A., and Case, D. A. (2006) J Mol Graph Model  
34. Jala, V. R., Shao, W. H., and Haribabu, B. (2005) J Biol Chem 280, 4880-4887 
35. Rao, J. V., Prakash, V., Rao, N. A., and Savithri, H. S. (2000) Eur J Biochem 267, 5967-5976 
36. Steeber, D. A., Engel, P., Miller, A. S., Sheetz, M. P., and Tedder, T. F. (1997) J Immunol 
159, 952-963 
37. Ogilvie, P., Thelen, S., Moepps, B., Gierschik, P., da Silva Campos, A. C., Baggiolini, M., 
and Thelen, M. (2004) J Immunol 172, 6715-6722 
38. Baneres, J. L., Martin, A., Hullot, P., Girard, J. P., Rossi, J. C., and Parello, J. (2003) J Mol 
Biol 329, 801-814 
39. Lefkowitz, R. J. (1998) J Biol Chem 273, 18677-18680 
40. Pitcher, J. A., Freedman, N. J., and Lefkowitz, R. J. (1998) Annu Rev Biochem 67, 653-692 
41. Hubbell, W. L., Cafiso, D. S., and Altenbach, C. (2000) Nat Struct Biol 7, 735-739 
42. Hubbell, W. L., Altenbach, C., Hubbell, C. M., and Khorana, H. G. (2003) Adv Protein Chem 
63, 243-290 
43. Farrens, D. L., Altenbach, C., Yang, K., Hubbell, W. L., and Khorana, H. G. (1996) Science 
274, 768-770 
44. Haribabu, B., Zhelev, D. V., Pridgen, B. C., Richardson, R. M., Ali, H., and Snyderman, R. 
(1999) J Biol Chem 274, 37087-37092 
45. Menard, L., Ferguson, S. S., Zhang, J., Lin, F. T., Lefkowitz, R. J., Caron, M. G., and Barak, 
L. S. (1997) Mol Pharmacol 51, 800-808 
46. Swaminath, G., Deupi, X., Lee, T. W., Zhu, W., Thian, F. S., Kobilka, T. S., and Kobilka, B. 
(2005) J Biol Chem 280, 22165-22171 










47. Tunaru, S., Lattig, J., Kero, J., Krause, G., and Offermanns, S. (2005) Mol Pharmacol 68, 
1271-1280 
48. Shin, N., Coates, E., Murgolo, N. J., Morse, K. L., Bayne, M., Strader, C. D., and Monsma, F. 
J., Jr. (2002) Mol Pharmacol 62, 38-47 
49. Gao, Z. G., Chen, A., Barak, D., Kim, S. K., Muller, C. E., and Jacobson, K. A. (2002) J Biol 
Chem 277, 19056-19063 
50. Quehenberger, O., Prossnitz, E. R., Cavanagh, S. L., Cochrane, C. G., and Ye, R. D. (1993) J 
Biol Chem 268, 18167-18175 
51. Hata, A. N., Lybrand, T. P., and Breyer, R. M. (2005) J Biol Chem 280, 32442-32451 
52. Blanpain, C., Doranz, B. J., Bondue, A., Govaerts, C., De Leener, A., Vassart, G., Doms, R. 
W., Proudfoot, A., and Parmentier, M. (2003) J Biol Chem 278, 5179-5187 
53. Colvin, R. A., Campanella, G. S., Manice, L. A., and Luster, A. D. (2006) Mol Cell Biol 26, 
5838-5849 
54. Schwartz, T. W., Frimurer, T. M., Holst, B., Rosenkilde, M. M., and Elling, C. E. (2006) 
Annu Rev Pharmacol Toxicol 46, 481-519 
55. Altenbach, C., Yang, K., Farrens, D. L., Farahbakhsh, Z. T., Khorana, H. G., and Hubbell, W. 
L. (1996) Biochemistry 35, 12470-12478 
56. Zhou, W., Flanagan, C., Ballesteros, J. A., Konvicka, K., Davidson, J. S., Weinstein, H., 
Millar, R. P., and Sealfon, S. C. (1994) Mol Pharmacol 45, 165-170 
57. Liu, W., Eilers, M., Patel, A. B., and Smith, S. O. (2004) J Mol Biol 337, 713-729 







Figure 1:  Leukotriene B4 binding site in human BLT1: (A) Schematic representation of human 
BLT1: The boundaries of each transmembrane (TM), extracellular (ECL) and intracellular (ICL) 
domains are derived from the molecular dynamics modeled structure of BLT1. The amino acid 
residues involved in the ligand binding and activation process are shaded green and red, respectively. 
Mutated residues in ECL2 showing no affect on the ligand binding or signaling are shaded in pink.  
(B) LTB4 docked structural model for BLT1 refined by restricted molecular dynamics (Methods): The 
seven transmembrane helices are colored TM1 (blue), TM2 (green), TM3 (yellow), TM4 (brown), 
TM5 (grey), TM6 (pink), TM7 (orange) and helix VIII red. LTB4 is rendered as space-filled with 
carbon atoms colored dark grey, hydrogen atoms in white and oxygen atoms in red. (C) The binding 
groove with LTB4 bound: Surface rendering of a cross section of BLT1 displaying the binding site 
with LTB4 docked (ligand represented as thick sticks, carbon atoms- green, oxygen atoms- red and 
hydrogen atoms –white).  
 
Figure 2:  Characterization of LTB4 binding site mutants in BLT1: (A) BLT1 Ligand binding 
pocket: Computational model of the BLT1 binding pocket with LTB4 bound, obtained by a consensus 
docking protocol (Methods). The predicted hydrogen bonding and electrostatic interactions are shown 
for E185, Y102, N241, R156, T157, H94 and LTB4 which stabilize the bound ligand in the pocket. 
Transmembrane helices III, IV, V, VI and ECL2 are shown with TM V rendered transparent. 
Hydrogen atoms are not displayed for clarity. (B) Stable Expression of BLT1 and its mutants in 
300.19 cells: Indirect immunofluorescence staining of 300.19 cells (300.19 - grey) and 300.19 stably 
expressing BLT1 and the indicated mutants with 12CA5 mAb and FITC-conjugated goat anti mouse 
IgG.(C and D) Saturation Ligand Binding: Representative saturation binding curve and scatchard plot 
of  [3H]-LTB4 binding to the 300.19 cells expressing BLT1 and Y102A. Data shown is 
representative of at least two independent experiments with triplicate measurements in each 
experiment. (E) Competition Ligand binding: Representative curves from one of three independent 
experiments of [3H]-LTB4 competition binding to the 300.19 cells expressing BLT1 or the indicated 










mutants. (F) Chemotaxis: Ligand dependent chemotaxis of BLT1 or its mutants was measured by 
transwell filters as described in methods. Data are the mean ± SD of cells counted from two individual 
wells (counted four fields per well) that migrated to the lower chamber for each concentration from a 
representative experiment of at least three repetitions. The color scheme in the panels b, c and d is as 
follows: BLT1 - black; YN-AA (Y102A, N241A) – orange; Y102A – red; N241A – blue; E185A – 
purple and H94A – cyan. 
 
Figure 3: Intracellular calcium release by BLT1 binding site mutants: 300.19 cells expressing 
BLT1 or mutants were loaded with Indo-1 and induced with various concentrations (0.1 nM-blue; 0.3 
nM-red; 1.0 nM-green; 3.0 nM-purple; 10 nM-orange; 30.0 nM-grey; 100 nM-brown; 300.0 nM-
black; 1000 nM-light blue; 3000 nM-pink) of LTB4 and the Ca2+ mobilization was measured. Data in 
(A) BLT1 (B) Y102A (C) N241A (D) H94A (E) Y102A-N241A is representative of at least three 
independent experiments. (F) Percentage maximum calcium response of BLT1 and mutants as 
compared to BLT1 is an average of three independent experiments for each mutant. 
 
Figure 4:  Characterization of LTB4 binding site mutants in ECL2 of BLT1: (A) Chemotaxis: 
Ligand dependent chemotaxis of BLT1 or its mutants was measured by transwell filters as described 
in methods. Data are the mean ± SD of cells counted from two individual wells (counted four fields 
per well) that migrated to the lower chamber for each concentration from a representative experiment 
of at least three repetitions. The color scheme in the panel A is as follows: BLT1 - black; R171A-
R178A – pink; RT/AA (R156A-T157A) – green; R156A – brown; T157A – grey.   (B, C, D, E) 
Intracellular calcium release: 300.19 cells expressing BLT1 mutants were loaded with Indo-1 and 
induced with various concentrations (0.1 nM-blue; 0.3 nM-red; 1.0 nM-green; 3.0 nM-purple; 10 nM-
orange; 30.0 nM-grey; 100 nM-brown; 300.0 nM-black; 1000 nM-light blue; 3000 nM-pink) of LTB4 
and the Ca2+ mobilization was measured. Data in (B) R171A-R178A (C) R156A-T157A (D) R156A 
(E) T157A is representative of at least three independent experiments. (F) Percentage maximum 
calcium response of BLT1 and mutants as compared to BLT1 is an average of three independent 
experiments for each mutant. 
 
Figure 5: Phosphorylation of BLT-1 and mutants: (A) 32P labeled 300-19 cells expressing BLT1 
or mutants (5 x 106 cells per sample) were incubated for 5 min with LTB4 as indicated. Cells were 
lysed and immunoprecipitated with 3F10 antibody and analyzed by SDS-Polyacrylamide gel 
electrophoresis and phosphor imager as described in methods. The data for each mutant is 
representative of at least three independent experiments with WT BLT1 as control except for 
E185A, which was performed only once. (B) Integrated counts were plotted as fold over basal 
level of phosphorylation for BLT1 and each of the mutants. 
 
Figure 6: Molecular models of Active and Inactive States of BLT1: Superimposition of the 
predicted inactive (blue) and active (green) state structural models of BLT1: (A) Lateral view of the 
structure of BLT1 outlining major helical movements along the vertical (y) axis.  (B) Top view 
showing rotation of helices around y-axis vector and translation of helices in the x-z plane. Helix VIII 
and loops are not shown for clarity.  LTB4 is rendered as space-filled with carbon atoms-cyan, 
hydrogen atoms-grey and oxygen atoms-red. 
 
Figure 7:  Interactions in the Activation Core of BLT1 and Characterization of mutants: (A) 
Inactive and (B) active states of BLT1: The D64-N281 and D64-N36 interactions are formed only in 
the active state. Heavy atom to heavy atom distances are shown. (C) Stable Expression of BLT1 and 
its mutants in 300.19 cells: Indirect immuno fluorescence staining of 300.19 cells (300.19 - grey) and 
300.19 stably expressing BLT1 and the indicated mutants with 12CA5 mAb and FITC-conjugated 
goat anti mouse IgG.  (D) Chemotaxis: Chemotaxis of BLT1 and its mutants was measured by 
transwell filters as described in methods. Data shown is representative of at least two 










independent experiments with duplicate measurements for each concentration and four fields 
in the hemocytometer were counted per well and averages were obtained.  
 
Figure 8: Functional analysis of BLT1 activation Core Mutants: (A-D) Calcium Mobilization: 
300.19 cells expressing BLT1 and mutants were loaded with Indo-1 and induced with various 
concentrations (0.1 nM-blue; 0.3 nM-red; 1.0 nM-green; 3.0 nM-purple; 10 nM-orange; 30.0 nM-
grey; 100 nM-brown; 300.0 nM-black; 500 nM-light blue) of LTB4 and the increase in fluorescence 
was measured as a ratio at wavelengths 405/490 nm. Data in (A) BLT1 (B) D64A (C) N281A is 
representative of at least three independent experiments. (D) Percentage maximum calcium response 
of BLT1 and mutants as compared to BLT1 is an average of three independent experiments for each 
mutant. (E) Phosphorylation of BLT-1 and mutants: 32P labeled 300-19 cells expressing BLT1 or 
mutants (5 x 106 cells per sample) were incubated for 5 min with LTB4 (100 nM) PMA (100 ng/ml) or 
buffer (control) as indicated. Cell lysates were immunoprecipitated with 3F10 antibody and analyzed 
by SDS-PAGE and phosphor imager as described in methods. The data for each mutant is 
representative of at least two independent experiments with WT BLT1 as control in each. (F) 
Integrated counts were plotted as fold over basal level of phosphorylation. (G) LTB4-induced co-
localization of BLT1 and β-arrestin: β-Arrestin-GFP (15 µg) is co-transfected along with either 
BLT1 or mutant receptors tagged with RFP (Mono) (25 µg) into RBL-2H3 cells. After the addition of 
LTB4 (0-time), red and green fluorescence images were collected every 10 seconds for 15 min using 
appropriate filters as described in methods. With time, co-localization of β-arrestin-GFP and receptor 
RFP (yellow punctate distribution) is seen with both native and N36A mutant receptors, where as in 
D64A weak translocation of β-arrestin was observed. Ligand-induced β-arrestin translocation was 
absent in S277-79A and N281A mutants. The images are representative of at least 10 separate single 
















Expression and functional properties of BLT1 and binding site mutants  
   
a: Relative surface expression of BLT1 (100%) and mutants (Fig 2B)  
b: EC50 measured from competition 3H-LTB4 binding assays (Fig 2E).  Data is representative of three 
independent experiments with triplicate measurements in each. 
c: Kd and Bmax measured from saturation binding assays (representative examples in Fig 2C and D). Data 
is representative of at least two independent experiments with triplicate measurements in each. 
d: The ligand concentration (nM) at maximum chemotaxis response (Fig 2F and Fig 4A) 
e: The ligand concentration (nM) at 50% of the maximum calcium response (Fig 3F and Fig 4F)  
nd: not determined; ND: No detectable binding, chemotaxis or calcium mobilization. 
 
 
 % Surface 
Expressiona 
EC 50 (nM)b Kd (nM)c Bmaxc sites/cell Chemotaxis Calcium Release
(EC 50)e 
BLT1 100 3.4 1.2  ± 0.17 17518 ± 450 3 0.427 
H94A 218 31.6 nd nd 100 25.3 
Y102A 132.6 21.2 10.1 ± 3.5 22027 ± 2987 30 9.8 
E185A 88.6 24.5 17.1 ± 5.3 23389 ± 4163 30 25 
N241A 101.8 12.4 7.6 ± 2.1 19908 ± 2031 30 20 
Y102A-N241A 121.6 56.6 58.9 ± 12.6 37418 ± 6876 300 279 
R156A-T157A 212.8 ND ND ND ND ND 
R156A 142 ND ND ND ND ND 
T157A 110 2.6 2.6 ± 0.14 74018 ± 1553 3 0.84 
R171A-R178A 140 5.5 1 ± 0.34 15575 ± 1559 3 0.32 













Expression and functional properties of BLT1 activation core mutants 
 
a: Relative surface expression of BLT1 (100%) and mutants (Fig 7C)  
b: EC50 measured from competition 3H-LTB4 binding assays. Data is representative of at least three 
independent experiments with triplicate measurements in each. 
c: Kd and Bmax measured from saturation binding assays. Data is representative of at least two 
independent experiments with triplicate measurements in each. 
d: % of the maximum calcium response at 10 nM LTB4 (Fig 8D) 
 
 % Surface 
Expressiona 
EC 50 (nM)b Kd (nM)c Bmaxc 
sites per cell 
Calcium Released
% activity at 10 nM
BLT1 100 3.4 1.2 ± 0.17 17518 ± 450 100 
N281A 177 3.6 1.4 ± 0.29 52877 ± 3725 14.8 
D64A 219 8.2 2.9 ± 0.63 36998 ± 2821 0.3 
N36A 111 2 1.2 ± 0.37 48201 ± 4587 103.6 
S277-79A 126 32.8 7.1 ± 2.8 29754 ± 5576 23.58 




























Conservation of polar residues in class A GPCRs  
The frequency of occurrence of the polar residues across 1636 class A GPCRs (www.GPCR.org) and 
percent conservation at congruent positions to that of the BLT1 (residue numbers shown in italics) 


















N 1636 46 504 32 9 1027 
S - 15 221 489 111 59 
C - 0 8 146 441 6 
H - 0 115 1 7 2 
D - 1495 4 17 8 213 
E - 44 11 13 28 6 
Q - 1 15 19 13 12 
T - 3 209 113 43 67 
Y - 3 10 14 33 30 
R - 0 33 12 17 15 
K - 1 22 26 17 16 
Polar residues 1636 1608 1152 882 727 1453 
Total residues 1636 1636 1636 1636 1636 1636 
       
% conservation 100 98.3 70.4 53.9 44.4 88.8 
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